FDA Approves Roche Pill After 62% Cut in Progression or Death Risk

The U.S. Food and Drug Administration approved Roche's Wilserdly (giredestrant) on November 16, 2026. The oral drug is cleared for use with everolimus in adults with advanced breast cancer that carries an ESR1 mutation. Roche sells it in the U.S. through its Genentech unit.
What happened
The approval covers adults with ER-positive, HER2-negative breast cancer that is locally advanced or has spread, and that has an ESR1 mutation. Their disease must have come back during or after hormone-based therapy given after surgery, or grown on at least one hormone-based treatment for spread disease. The FDA also cleared the FoundationOne Liquid CDx blood test as a companion diagnostic to find the mutation.
The decision rests on the evERA Breast Cancer trial, a randomized, open-label study in 373 adults. Of those, 207 had ESR1 mutations. Patients took giredestrant 30 mg once a day or their doctor's choice of exemestane, fulvestrant or tamoxifen. Everyone also took everolimus.
In the ESR1 group, the FDA reported a median of 10 months before the cancer grew or the patient died, against 5.5 months in the comparison arm. The hazard ratio was 0.38. Genentech describes this as a 62% lower risk of progression or death. Tumours shrank in 27% of patients on giredestrant, versus 14% on the comparison. Overall survival data are not yet mature.
The most common side effects included mouth sores, rash, fatigue, diarrhea, muscle and bone pain, lung inflammation and nausea. The label warns about a slow heart rate and harm to an unborn baby. The FDA said it approved the application 4 weeks before its goal date.
Why it matters
Giredestrant is a selective estrogen receptor degrader, or SERD, taken by mouth. ESR1 mutations are a common way these tumours stop responding to hormone therapy. Genentech says up to 40% of people with HR-positive metastatic breast cancer develop them.
The drug matters for Roche too. STAT reported that the company has said giredestrant could become its top-selling product ever, though estimates vary. STAT also noted that Roche has fallen behind rival drugmakers in cancer in recent years.
A second FDA decision is close. Genentech said an application to use giredestrant after surgery in early breast cancer, based on the lidERA trial, is under Priority Review. A decision is expected by November 30.
What it means for people in the industry
Genentech expects the drug to reach U.S. pharmacies in the coming weeks. It did not give a list price. The FDA review ran under Project Orbis, which named Health Canada and Israel's Ministry of Health as partners. Those reviews may still be open, so a Canadian decision is one to watch. Genentech said more filings are underway outside the U.S.
For oncology teams in sales, medical affairs and diagnostics, the approval ties the drug to blood-based ESR1 testing. Watch for the early breast cancer ruling and for overall survival data from evERA.
See open pharma jobs in the US and Canada
Sources
- FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer, U.S. Food and Drug Administration
- FDA Approves Genentech's WILSERDLY (Giredestrant), a Next-Generation Oral SERD, for ER-Positive, ESR1-Mutated Advanced Breast Cancer, Genentech via BioSpace
- FDA approves new breast cancer drug, providing new option for some patients, boost for Roche, STAT
Check Your Supplement Interactions
Use our AI-powered checker to analyze supplement safety and interactions.
Open Interaction Checker →Comments (0)
This article is for informational purposes only and does not constitute medical or investment advice. It was written with AI assistance from the sources listed above. Check the original sources before relying on any detail.